Nanocrystalline Epstein-Barr virus decoys.
A novel biotechnology is introduced by way of the successful synthesis of nanocrystalline Epstein-Barr virus (EBV) decoys having specific in vivo immunogenic activity.  Assembled from ultrafine surface modified tin oxide and purified DNA-free isolated EBV envelope proteins, the decoys consisted of less than 150 nm units whose electrophoretic mobilities were similar to whole EBV; whose outer coats were strongly immunoreactive with murine monoclonal anti-EBV antibodies; and which elicited immunospecific neutralizing anti-EBV antibodies in the rabbit.  The development of this carrier technology for vaccine preparations is suggested.
Department of Pathology and Laboratory Medicine, School of Medicine, University of California, Los Angeles 90024.
N
N
Kossovsky
A
A
Gelman
E
E
Sponsler
D
D
Millett
D000818:Animals; D000914:Antibodies, Viral / Q000096:biosynthesis; D004337:Drug Carriers; D004353:Drug Evaluation, Preclinical; D004854:Herpesvirus 4, Human / Q000276:immunology*; D006801:Humans; D008565:Membrane Proteins; D010316:Particle Size; D011817:Rabbits; D013499:Surface Properties; D013501:Surface-Active Agents; D014001:Tin; D014759:Viral Envelope Proteins; D014765:Viral Vaccines